Clinical trials
Renal Cell Cancer Metastatic clinical trials
Below are recruiting renal cell cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 601 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT06714357RecruitingPhase 2
Valproic Acid to Boost Anti-EGFR in Colorectal Cancer
This trial tests whether adding valproic acid to standard anti-EGFR plus irinotecan can stop or reverse resistance in metastatic colorectal cancer. It is for patients who previously responded well to an anti-EGFR drug and then progressed.
Caserta, CEAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT06401980RecruitingPhase 2
Darolutamide for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
AarauAges 18 years+ - NCT07500298RecruitingPhase 1
New drug plus standard chemo for spread colorectal cancer
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
Houston, TexasAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT06441773Recruiting
Lung rehab for advanced lung cancer on maintenance therapy
This study tests if a respiratory (breathing) rehabilitation program can improve quality of life for people with advanced non-small cell lung cancer who are on maintenance treatment after initial chemotherapy and immunotherapy.
BrestAges 18 years+ - NCT04829708RecruitingPhase 3
Preventing brain spread in limited-stage small cell lung cancer
This trial compares two ways to manage limited-stage small cell lung cancer that has improved after initial chemotherapy and radiation. Participants will either get preventive brain radiation or have regular brain MRI scans instead, to see which approach is safer and works better.
Jinan, ShandongAges 18–75 - NCT07217028RecruitingPhase 1
Safety study of a new PET tracer for head and neck cancer
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
Nashville, TennesseeAges 18 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+ - NCT06613269RecruitingPhase 2
PET-guided radiation therapy for clear cell kidney cancer
This trial tests whether a special PET/CT scan (68Ga-NY104) can help guide radiation therapy for people with clear cell kidney cancer. The goal is to make radiation more precise and effective for treating tumors that haven't spread too much.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06690697RecruitingPhase 2
Toripalimab and JS004 for advanced kidney cancer
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07389629RecruitingPhase 2
Combination therapy before surgery for kidney cancer
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
GuangzhouAges 18–80 - NCT07386158RecruitingPhase 2
Immunotherapy before surgery for clear cell kidney cancer
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
Guangzhou, Other (Non U.s.)Ages 18–85 - NCT06190899RecruitingPhase 1/Phase 2
Testing gedatolisib plus darolutamide in advanced prostate cancer
This trial tests a new combination of two drugs, gedatolisib and darolutamide, in men with prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can help control the cancer when standard treatments have stopped working.
Detroit, MichiganAges 18 years+ - NCT06364631RecruitingPhase 3
Testing a new approach for advanced kidney cancer
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
ViennaAges 18 years+ - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07020065RecruitingPhase 2
Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Fribourg, Villars-sur-GlâneAges 70 years+ - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT07282834RecruitingPhase 2
Comparing two types of heated chemo for abdominal cancer spread
This trial tests if giving heated chemotherapy as a mist (aerosol) is better than as a liquid for cancer that has spread to the lining of the abdomen. It is for people who have already had at least three months of standard chemo but still have disease and cannot have surgery right now.
Pittsburgh, PennsylvaniaAges 18–80 - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70
Hear when a new Renal Cell Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal cell cancer metastatic?
- Yes. Clin2 currently lists 601 recruiting renal cell cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cell cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cell cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.